CY1122436T1 - Αντισωματα εναντι του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egfr) - Google Patents
Αντισωματα εναντι του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egfr)Info
- Publication number
- CY1122436T1 CY1122436T1 CY20191101349T CY191101349T CY1122436T1 CY 1122436 T1 CY1122436 T1 CY 1122436T1 CY 20191101349 T CY20191101349 T CY 20191101349T CY 191101349 T CY191101349 T CY 191101349T CY 1122436 T1 CY1122436 T1 CY 1122436T1
- Authority
- CY
- Cyprus
- Prior art keywords
- egfr
- antibodies against
- growth factor
- factor receptor
- epitanial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G01N33/57575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462005887P | 2014-05-30 | 2014-05-30 | |
| PCT/US2015/033402 WO2015184403A2 (en) | 2014-05-30 | 2015-05-29 | Anti-epidermal growth factor receptor (egfr) antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122436T1 true CY1122436T1 (el) | 2021-01-27 |
Family
ID=54700080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101349T CY1122436T1 (el) | 2014-05-30 | 2019-12-20 | Αντισωματα εναντι του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egfr) |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10584171B2 (index.php) |
| EP (2) | EP3613433B1 (index.php) |
| JP (1) | JP6691872B2 (index.php) |
| KR (1) | KR102366644B1 (index.php) |
| CN (1) | CN106714830B (index.php) |
| AU (1) | AU2015266664B2 (index.php) |
| CY (1) | CY1122436T1 (index.php) |
| DK (1) | DK3148581T3 (index.php) |
| ES (2) | ES2905777T3 (index.php) |
| HR (1) | HRP20192038T1 (index.php) |
| HU (1) | HUE047113T2 (index.php) |
| PL (1) | PL3148581T3 (index.php) |
| PT (1) | PT3148581T (index.php) |
| SG (1) | SG11201609959UA (index.php) |
| SI (1) | SI3148581T1 (index.php) |
| SM (1) | SMT201900745T1 (index.php) |
| TW (1) | TWI689520B (index.php) |
| WO (1) | WO2015184403A2 (index.php) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201900745T1 (it) | 2014-05-30 | 2020-01-14 | Henlix Biotech Co Ltd | Anticopri anti-recettore del fattore di crescita epidermico (egfr) |
| WO2018078158A1 (en) * | 2016-10-31 | 2018-05-03 | Hexal Ag | Antibody preparation |
| WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| US12336995B2 (en) | 2018-09-10 | 2025-06-24 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2021170068A1 (en) * | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| CN113855784B (zh) * | 2021-09-26 | 2025-04-15 | 深圳辰扬生物科技有限公司 | 多肽的抗抑郁、抗焦虑用途及复合体 |
| WO2024051762A1 (en) * | 2022-09-07 | 2024-03-14 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Anti-trop2/egfr antibodies and uses thereof |
| WO2024061297A1 (en) * | 2022-09-22 | 2024-03-28 | Shanghai Henlius Biotech , Inc. | Anti-b7h3 antibodies, multispecific antibodies and methods of use |
| AU2024269443A1 (en) * | 2023-05-09 | 2025-12-11 | Shanghai Henlius Biologics Co., Ltd. | Anti-epidermal growth factor receptor (egfr) antibody-drug conjugate and use thereof |
| CN120329440A (zh) * | 2024-01-18 | 2025-07-18 | 烁微生物医药(上海)有限公司 | 特异性结合hEGFR的单克隆抗体及双特异性抗体 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
| US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
| ATE108068T1 (de) | 1987-09-23 | 1994-07-15 | Bristol Myers Squibb Co | Antikörper-heterokonjugate zur töting von hiv- infizierten zellen. |
| ZA894792B (en) | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
| ES2013978A4 (es) | 1988-06-24 | 1990-06-16 | Dow Chemical Co | Compuestos de enlace ionico bifuncionales macrociclicos, complejos de ellos y sus anticuerpos conjugados |
| US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
| US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
| US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
| DE68926248T2 (de) | 1989-09-29 | 1996-12-19 | Oncogene Science Inc | p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CN102416176A (zh) | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MX353234B (es) | 1999-01-15 | 2018-01-08 | Genentech Inc | Variantes de polipeptidos con función efectora alterada. |
| DK1176195T3 (da) | 1999-04-09 | 2013-06-24 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| NZ591970A (en) | 2003-01-22 | 2012-11-30 | Roche Glycart Ag | Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function |
| CA2534077A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| EP2502935B1 (en) | 2003-08-22 | 2017-03-29 | Biogen MA Inc. | Improved antibodies having altered effector function and methods for making the same |
| EP1663306A2 (en) | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
| HUE042914T2 (hu) | 2003-11-05 | 2019-07-29 | Roche Glycart Ag | CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval |
| US20110142822A1 (en) * | 2004-06-14 | 2011-06-16 | Kussie Paul H | Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION |
| US20090215639A1 (en) | 2005-04-26 | 2009-08-27 | Bioren, Inc. | Method of Producing Human IgG Antibodies with Enhanced Effector Functions |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| TWI478940B (zh) | 2005-08-26 | 2015-04-01 | Roche Glycart Ag | 具有經改變細胞傳訊活性之改質抗原結合分子 |
| PT1951759E (pt) | 2005-11-12 | 2010-04-01 | Lilly Co Eli | Anticorpos anti-egfr |
| US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| ES2639056T3 (es) | 2009-10-28 | 2017-10-25 | Abbvie Biotherapeutics Inc. | Anticuerpos anti-EGFR y sus usos |
| EA201290241A1 (ru) * | 2009-10-29 | 2013-02-28 | Янссен Байотек Инк. | Изменение гликозилирования антител |
| EP2632490A4 (en) | 2010-10-29 | 2014-10-22 | Immunogen Inc | NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF |
| CA2831820C (en) * | 2011-04-01 | 2021-05-25 | Universitat Stuttgart | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof |
| SG194111A1 (en) * | 2011-04-07 | 2013-11-29 | Amgen Inc | Novel egfr binding proteins |
| AU2013229786B2 (en) * | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| WO2014138449A1 (en) * | 2013-03-06 | 2014-09-12 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
| DK3024851T3 (en) * | 2013-07-25 | 2018-08-06 | Cytomx Therapeutics Inc | MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT |
| SMT201900745T1 (it) | 2014-05-30 | 2020-01-14 | Henlix Biotech Co Ltd | Anticopri anti-recettore del fattore di crescita epidermico (egfr) |
-
2015
- 2015-05-29 SM SM20190745T patent/SMT201900745T1/it unknown
- 2015-05-29 KR KR1020167036460A patent/KR102366644B1/ko active Active
- 2015-05-29 SG SG11201609959UA patent/SG11201609959UA/en unknown
- 2015-05-29 CN CN201580029644.6A patent/CN106714830B/zh active Active
- 2015-05-29 ES ES19201262T patent/ES2905777T3/es active Active
- 2015-05-29 PL PL15800314T patent/PL3148581T3/pl unknown
- 2015-05-29 US US15/315,371 patent/US10584171B2/en active Active
- 2015-05-29 AU AU2015266664A patent/AU2015266664B2/en active Active
- 2015-05-29 HR HRP20192038TT patent/HRP20192038T1/hr unknown
- 2015-05-29 TW TW104117520A patent/TWI689520B/zh active
- 2015-05-29 WO PCT/US2015/033402 patent/WO2015184403A2/en not_active Ceased
- 2015-05-29 JP JP2016571061A patent/JP6691872B2/ja active Active
- 2015-05-29 SI SI201531048T patent/SI3148581T1/sl unknown
- 2015-05-29 EP EP19201262.3A patent/EP3613433B1/en active Active
- 2015-05-29 HU HUE15800314A patent/HUE047113T2/hu unknown
- 2015-05-29 PT PT158003145T patent/PT3148581T/pt unknown
- 2015-05-29 ES ES15800314T patent/ES2761675T3/es active Active
- 2015-05-29 DK DK15800314.5T patent/DK3148581T3/da active
- 2015-05-29 EP EP15800314.5A patent/EP3148581B1/en active Active
-
2019
- 2019-12-20 CY CY20191101349T patent/CY1122436T1/el unknown
-
2020
- 2020-02-06 US US16/784,166 patent/US11261255B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3148581T3 (da) | 2020-01-13 |
| EP3613433A1 (en) | 2020-02-26 |
| KR20170010855A (ko) | 2017-02-01 |
| WO2015184403A3 (en) | 2016-01-21 |
| SG11201609959UA (en) | 2016-12-29 |
| US20200223929A1 (en) | 2020-07-16 |
| AU2015266664B2 (en) | 2020-04-30 |
| SI3148581T1 (sl) | 2020-02-28 |
| EP3148581A4 (en) | 2017-11-01 |
| EP3148581B1 (en) | 2019-10-09 |
| PT3148581T (pt) | 2020-01-06 |
| TW201613971A (en) | 2016-04-16 |
| JP6691872B2 (ja) | 2020-05-13 |
| US20170218073A1 (en) | 2017-08-03 |
| ES2761675T3 (es) | 2020-05-20 |
| CN106714830A (zh) | 2017-05-24 |
| SMT201900745T1 (it) | 2020-01-14 |
| US10584171B2 (en) | 2020-03-10 |
| CN106714830B (zh) | 2020-08-25 |
| JP2017521054A (ja) | 2017-08-03 |
| HUE047113T2 (hu) | 2020-04-28 |
| KR102366644B1 (ko) | 2022-02-22 |
| PL3148581T3 (pl) | 2020-05-18 |
| WO2015184403A2 (en) | 2015-12-03 |
| EP3613433B1 (en) | 2022-01-05 |
| US11261255B2 (en) | 2022-03-01 |
| TWI689520B (zh) | 2020-04-01 |
| EP3148581A2 (en) | 2017-04-05 |
| AU2015266664A1 (en) | 2016-12-08 |
| HRP20192038T1 (hr) | 2020-02-07 |
| ES2905777T3 (es) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122436T1 (el) | Αντισωματα εναντι του υποδοχεα του επιδερμικου αυξητικου παραγοντα (egfr) | |
| CY1124867T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
| CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
| CY1125084T1 (el) | Εμβολια νουκλεϊκου οξεος | |
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
| SA519401072B1 (ar) | Bcma مستقبلات مولد ضد خيمري تستهدف وطرق استخدامها | |
| BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
| CY1122642T1 (el) | Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου | |
| UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| NZ743881A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| EA201890630A1 (ru) | Антитела против pd-1 и способы их применения | |
| MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| MY199683A (en) | Anti-pd-1 antibodies | |
| MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| IL263382A (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
| BR112016017986A2 (pt) | anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos de produção de um anticorpo, de tratamento do câncer, de tratamento de uma doença e de detecção de jagged1 humana em uma amostra biológica, imunoconjugado, formulação farmacêutica e uso do anticorpo | |
| HK1218860A1 (zh) | 卵巢癌疫苗及接种方法 |